Strategic Plan On The Development of Traditional Chinese Medicine (2016-30)

Broker's Calls

'Buy' Tianjin Zhong Xin as TCM demand could rebound strongly: UOB Kay Hian

Despite the impact from the novel coronavirus (Covid-19) lockdown measures, UOB KayHian is still bullish on Tianjin Zhong Xin Pharmaceutical Group Corp.
×